Skip to main content

Abbott Raises Stake in Ibis Biosciences by $20M; Retains Right to Buy

NEW YORK (GenomeWeb News) – Abbott has invested a second $20 million in pathogen detection developer Ibis Biosciences, upping its stake in the company to 18.6 percent, Ibis parent firm Isis Pharmaceuticals said today.
 
The agreement follows a $20 million investment that Abbott made in January that gave it a 10.25 percent stake in the firm.
 
Ibis plans to use the cash to develop its T5000 Biosensor System, a system for rapidly identifying and characterizing infectious agents, including pandemic diseases, emerging or previously unknown pathogens, and hospital-acquired infections.
 
Abbott retains the exclusive option to purchase the remaining equity in Ibis for an additional $175 million to $190 million through June 30, 2009.
 
If Abbott purchases Ibis, it will owe Isis earn-out money related to certain sales.
 
"We are aggressively accelerating the expansion of our commercial products into larger market opportunities, and this recent financing from Abbott will provide the capital to continue on this path," said Ibis president Michael Treble in a statement.
The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.